摘要
目的:探讨小儿骨肉瘤患者大剂量甲氨蝶呤(HD-MTX)化疗后的肝损害特点,为临床提供参考。方法:某院2012年1—12月儿科使用HD-MTX化疗的骨肉瘤患儿25例,共进行了55次的化疗。监测其化疗后丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)的变化,以观察小儿HD-MTX化疗后肝损害的发生率、毒性分级、同一患儿不同疗程中的肝损害特点以及预后。结果:25例患儿使用HD-MTX化疗后肝损害发生率为100%。在25例患儿化疗的55个疗程中,共有51个疗程出现肝损害,发生率为92.73%,肝损害以3级为主,且同一患儿不同疗程中肝损害程度相近或相同。患儿预后良好,未出现化疗延迟情况。结论:临床医师、药师应重视小儿HD-MTX化疗后肝损害,以保证化疗的顺利进行。
OBJECtIVE To investigate the characteristics of liver damage in children with osteosarcoma after high-dose methotrexate （HD-MTX） chemotherapy,and provide a reference for its clinical application. METHODS The change of alanine aminotransferase （ALT） and aspartate aminotransferase fAST）, the incidence of liver damage, toxicity grading, liver damage characteristics in the different courses of the same child and the prognosis of 25 children with a total of 55 times of HD-MTX chemotherapy, were observed from January 2012 to December 2012, in our hospital. RESULTS 25 cases children received HD-MTX chemotherapy, the incidence of liver damage was 100%. In the total 55 courses HD-MTX chemotherapy of 25 chil- dren, 51 courses occurred liver damage, the incidence was 92. 73%, mainly 3 degrees of liver damage,and the different courses of the same child were similar or the same degree of liver damage. All patients with good prognosis, chemotherapy delay did not appear. CONCLUSION Clinical physicians and pharmacists should be alert to the liver damage caused by HD-MTX, in or- der to ensure the smooth progress of chemotherapy.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2014年第4期303-305,共3页
Chinese Journal of Hospital Pharmacy
关键词
大剂量甲氨蝶呤
小儿
肝损害
high-dose methotrexate
children
liver damage
